0 works0 citations0 h-index

Sylvia Adams

NYU Langone Health(US)The University of Texas at San Antonio(US)New York University(US)

Publications by Year

Research Areas

Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Advanced Breast Cancer Therapies, Chronic Obstructive Pulmonary Disease (COPD) Research, Cancer Genomics and Diagnostics

Most-Cited Works

→ Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer(2018)4,261 cited
→ The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014(2014)3,065 cited
→ Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199(2014)1,327 cited
→ Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial(2019)1,171 cited
→ Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers(2019)859 cited
→ NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis

(2017)

787 cited

→ Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors(2017)784 cited

→ Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study(2018)771 cited

→ Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research(2017)706 cited

→ Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial(2015)642 cited